/NXSCF
NXSCF Stock - Next Science Limited
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$0.08+0.00%
+$0.00 (+0.00%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.09
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NXSCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.08 – $0.08
TARGET (TP)$0.09
STOP LOSS$0.07
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$0.11
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $22.82M | $22.18M | $11.71M | $8.95M | $3.44M |
| Gross Profit | $18.44M | $16.23M | $11.90M | $5.94M | $2.47M |
| Gross Margin | 80.8% | 73.2% | 101.6% | 66.4% | 71.7% |
| Operating Income | $-10,304,109 | $-15,954,085 | $-12,703,007 | $-9,277,983 | $-14,046,096 |
| Net Income | $-10,586,018 | $-24,512,868 | $-18,295,928 | $-9,028,924 | $-13,351,938 |
| Net Margin | -46.4% | -110.5% | -156.2% | -100.9% | -388.0% |
| EPS | $-0.04 | $-0.07 | $-0.09 | $-0.05 | $-0.07 |
Company Overview
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NXSCFBeat Rate
100%
Last 9 quarters
Avg Surprise
+48.9%
EPS vs Estimate
Beats / Misses
9/0
Last 12 quarters
Latest EPS
$-0.01
Q3 2025
EPS Surprise History
Q1 23
+25.2%
$-0.01vs$-0.02
Q2 23
No data
Q1 24
No data
Q1 24
+19.7%
$-0.02vs$-0.03
Q2 24
No data
Q3 24
+64.8%
$-0.01vs$-0.02
Q1 25
+50.5%
$-0.01vs$-0.02
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q3 2025 | Sep 4, 2025 | — | $-0.01 | — | — |
Q2 2025 | Apr 24, 2025 | — | — | — | — |
Q1 2025 | Feb 28, 2025 | $-0.02 | $-0.01 | +50.5% | ✓ BEAT |
Q4 2024 | Oct 21, 2024 | — | — | — | — |
Q3 2024 | Jul 24, 2024 | $-0.02 | $-0.01 | +64.8% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 27, 2024 | $-0.03 | $-0.02 | +19.7% | ✓ BEAT |
Q1 2024 | Jan 30, 2024 | — | $-0.01 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 31, 2023 | $-0.02 | $-0.01 | +25.2% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.01 | $-0.01 | +23.4% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.02 | — | — |
Q3 2022 | Aug 24, 2022 | $-0.02 | $-0.01 | +47.9% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | — | $-0.02 | — | — |
Q1 2022 | Feb 22, 2022 | $-0.02 | $-0.01 | +55.2% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Q3 2021 | Aug 29, 2021 | $-0.04 | $-0.01 | +76.7% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | — | $-0.02 | — | — |
Q1 2021 | Feb 21, 2021 | $-0.04 | $-0.01 | +76.4% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about NXSCF
What is NXSCF's current stock price?
Next Science Limited (NXSCF) is currently trading at $0.08 per share. The stock has moved +0.00% today.
What is the analyst price target for NXSCF?
No analyst price targets are currently available for this stock.
What sector is Next Science Limited in?
Next Science Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is NXSCF's market cap?
Next Science Limited has a market capitalization of $0.02 billion, making it a small-cap company.
Does NXSCF pay dividends?
No, Next Science Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAHGIF
Alternate Health Corp.
$0.00
Mkt Cap: $0.0B
CNTMF
Fluent Corp.
$0.06
Mkt Cap: $0.0B
CWBHF
Charlotte's Web Holdings, Inc.
$0.21
Mkt Cap: $0.0B
ELXMF
Nova Eye Medical Limited
$0.00
Mkt Cap: $0.0B
EOFBF
Ecofibre Limited
$0.00
Mkt Cap: $0.0B
HSTI
High Sierra Technologies, Inc.
$1.40
Mkt Cap: $0.0B
ITHUF
iAnthus Capital Holdings, Inc.
$0.01
Mkt Cap: $0.0B
MEDIF
MediPharm Labs Corp.
$0.05
Mkt Cap: $0.0B
PVCT
Provectus Biopharmaceuticals, Inc.
$0.06
Mkt Cap: $0.0B
WOWU
WOWI, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to NXSCF for comparison